ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last561 to 580 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Dalcetrapib (RO4607381) vs Placebo: Composite Endpoint:All Cause Mortality226 of 7,938

229 of 7,933

-0.0 points

-0.6 to 0.5

15,871NCT00658515

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Dalcetrapib (RO4607381) vs Placebo: serious adverse events1,688 of 7,938

1,692 of 7,933

-0.1 points

-1.3 to 1.2

15,871NCT00658515

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Cases vs Controls: Number of New Onset Skin Cancers in the Non-white Ethnicity Subgroup9 of 3,179

66 of 12,663

-0.2 points

-0.4 to 0.0

15,842NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Darapladib vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Non-fatal Stroke During the Time Period for Follow-up of CV Events926 of 7,924

962 of 7,904

-0.5 points

-1.5 to 0.5

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With First Occurrence of MI (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events361 of 7,924

405 of 7,904

-0.6 points

-1.2 to 0.1

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With All-cause Mortality During the Time Period for Vital Status582 of 7,924

577 of 7,904

0.0 points

-0.8 to 0.9

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events (Coronary Heart Disease [CHD] Death, Non-fatal MI, or Urgent Coronary Revascularization [CR] for MI) During the Time Period for Follow-up (FU) of CV Events737 of 7,924

814 of 7,904

-1.0 points

-1.9 to -0.1

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events769 of 7,924

819 of 7,904

-0.7 points

-1.6 to 0.3

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With CV Death During the Time Period for Follow-up of CV Events359 of 7,924

373 of 7,904

-0.2 points

-0.8 to 0.5

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events154 of 7,924

152 of 7,904

0.0 points

-0.4 to 0.5

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: deaths from any cause582 of 7,924

577 of 7,904

0.0 points

-0.8 to 0.9

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During Time Period for FU of CV Events1,159 of 7,924

1,269 of 7,904

-1.4 points

-2.6 to -0.3

15,828NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Darapladib vs Placebo: serious adverse events3,369 of 7,912

3,448 of 7,890

-1.1 points

-2.7 to 0.4

15,802NCT00799903

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

AAC Only vs AAC + TMCP: Number of Patients With Documentation of Brief Advice7,086 of 9,145

5,579 of 6,641

-6.5 points

-7.7 to -5.3

15,786NCT02764385

Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals

IBD Cases vs Matched Controls (Reference Group): Stream 1: Relative Risk of Any Mental Health Condition299 of 3,423

811 of 12,256

2.1 points

1.1 to 3.2

15,679NCT05206734

Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health

Clostridium Difficile Vaccine vs Placebo: Number of Participants With Recurrent Episodes of CDI (Definition 2) After Dose 35 of 7,707

3 of 7,805

0.0 points

-0.1 to 0.1

15,512NCT03090191

Clostridium Difficile Vaccine Efficacy Trial

Omega-3 vs Placebo Omega-3: Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)83 of 7,740

99 of 7,740

-0.2 points

-0.6 to 0.1

15,480NCT00135226

ASCEND: A Study of Cardiovascular Events iN Diabetes

Aspirin vs Placebo Aspirin: Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only)87 of 7,740

82 of 7,740

0.1 points

-0.3 to 0.4

15,480NCT00135226

ASCEND: A Study of Cardiovascular Events iN Diabetes

Aspirin vs Placebo Aspirin: Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)314 of 7,740

245 of 7,740

0.9 points

0.3 to 1.5

15,480NCT00135226

ASCEND: A Study of Cardiovascular Events iN Diabetes

Aspirin vs Placebo Aspirin: Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)157 of 7,740

158 of 7,740

-0.0 points

-0.5 to 0.4

15,480NCT00135226

ASCEND: A Study of Cardiovascular Events iN Diabetes

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=29

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00658515-475d3899",
        "title": "Dalcetrapib (RO4607381) vs Placebo: Composite Endpoint:All Cause Mortality",
        "summary": "226 of 7938 against 229 of 7933; risk difference -0.0 points, 95% interval -0.6 to 0.5; NCT00658515, A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT00658515-475d3899",
        "nct_id": "NCT00658515",
        "kind": "outcome",
        "participants": 15871,
        "risk_difference": {
          "value": -0.0003961115892589587,
          "lower": -0.005608294176255342,
          "upper": 0.004813888193854889
        },
        "group_1": "226 of 7,938",
        "group_2": "229 of 7,933",
        "difference": "-0.0 points",
        "interval": "-0.6 to 0.5",
        "trial_title": "A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome"
      },
      {
        "id": "NCT00658515-sae",
        "title": "Dalcetrapib (RO4607381) vs Placebo: serious adverse events",
        "summary": "1688 of 7938 against 1692 of 7933; risk difference -0.1 points, 95% interval -1.3 to 1.2; NCT00658515, A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT00658515-sae",
        "nct_id": "NCT00658515",
        "kind": "serious-adverse-events",
        "participants": 15871,
        "risk_difference": {
          "value": -0.0006382503606276457,
          "lower": -0.013376982033315284,
          "upper": 0.01210051797157327
        },
        "group_1": "1,688 of 7,938",
        "group_2": "1,692 of 7,933",
        "difference": "-0.1 points",
        "interval": "-1.3 to 1.2",
        "trial_title": "A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=30",
  "request_id": "YJJjCjUPqGwb19bC"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?